otonomy
completes
patient
enrollment
phase
trial
ménière
disease
san
diego
globe
newswire
otonomy
nasdaq
otic
biopharmaceutical
company
dedicated
development
innovative
therapeutics
neurotology
today
announced
completion
patient
enrollment
phase
clinical
trial
otividex
ménière
disease
total
patients
enrolled
trial
exceeding
target
patients
following
randomization
treatment
single
intratympanic
injection
otividex
placebo
patients
followed
three
months
completion
enrollment
important
milestone
otividex
program
keeps
us
track
announcing
results
first
quarter
positive
results
trial
positive
trial
results
already
would
expect
submit
new
drug
application
third
quarter
said
david
weber
president
ceo
otonomy
grateful
patients
investigators
participating
trial
also
appreciate
high
compliance
continues
demonstrated
patients
reporting
daily
vertigo
episodes
believe
reflects
high
disease
burden
unmet
medical
need
ménière
disease
otonomy
otonomy
biopharmaceutical
company
dedicated
development
innovative
therapeutics
neurotology
company
pioneered
application
drug
delivery
technology
ear
order
develop
products
achieve
sustained
drug
exposure
single
local
administration
approach
covered
broad
patent
estate
utilized
develop
pipeline
products
addressing
important
unmet
medical
needs
including
ménière
disease
hearing
loss
tinnitus
additional
information
please
visit
cautionary
note
regarding
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
generally
relate
future
events
future
financial
operating
performance
otonomy
statements
press
release
include
limited
statements
relating
timing
announcement
results
conduct
activity
ongoing
phase
clinical
trial
otividex
ménière
disease
expectations
regarding
submission
new
drug
application
statements
otonomy
president
ceo
otonomy
expectations
regarding
matters
may
materialize
actual
results
future
periods
subject
risks
uncertainties
actual
results
may
differ
materially
indicated
statements
result
risks
uncertainties
including
limited
delays
disruption
resulting
pandemic
governmental
responses
pandemic
including
current
future
impacts
otonomy
operations
manufacturing
product
candidates
progression
current
clinical
trials
patient
conduct
compliance
uncertainties
inherent
clinical
drug
development
process
including
without
limitation
otonomy
ability
adequately
demonstrate
safety
efficacy
product
candidates
nonclinical
clinical
results
product
candidates
challenges
related
patient
enrollment
conduct
compliance
clinical
trials
integrity
outcomes
clinical
trials
side
effects
adverse
events
associated
otonomy
product
candidates
otonomy
dependence
third
parties
conduct
nonclinical
studies
clinical
trials
expectations
regarding
potential
therapy
benefits
risks
information
regarding
foregoing
additional
risks
may
found
section
entitled
risk
factors
otonomy
quarterly
report
form
filed
securities
exchange
commission
sec
august
otonomy
future
reports
filed
sec
statements
press
release
based
information
available
otonomy
date
hereof
otonomy
disclaims
obligation
update
statements
except
required
law
contacts
media
inquiries
spectrum
science
ramsey
vice
president
cramsey
investor
inquiries
westwicke
icr
robert
uhl
managing
director
